Connecticut Designates Kratom as Schedule 1 Controlled Substance, Imposing Immediate Ban

Connecticut Designates Kratom as Schedule 1 Controlled Substance, Imposing Immediate Ban

HARTFORD, CT – March 24, 2026 – In a significant move impacting the kratom industry, Connecticut has officially designated kratom, along with six other substances, as a Schedule 1 controlled substance. This designation, effective March 25, 2026, makes it illegal to possess, manufacture, sell, or distribute kratom within the state. The announcement came during a press conference held by Attorney General William Tong and the Connecticut Department of Consumer Protection (DCP) on Monday, March 23, 2026.

What Happened: A Swift Regulatory Shift

The decision to classify Mitragyna speciosa (kratom), including its leaves, stem, and any extracts, as a Schedule 1 controlled substance follows a period of legislative and regulatory review. Connecticut's Legislative Regulation Review Committee unanimously approved regulations on February 25, 2026, solidifying the ban. This action also includes kratom derivative 7-hydroxymitragynine (7-OH), bromazolam, flubromazolam, nitazenes, tianeptine, and phenibut.

Attorney General William Tong explicitly stated that as of Wednesday, March 25, it would be illegal to engage in any activities related to these substances, including kratom. He emphasized the unregulated nature of these products, noting they were "never regulated, tested, or otherwise deemed safe for human consumption," despite being marketed as health products. The DCP has advised businesses to immediately remove all designated Schedule 1 controlled substances from shelves and either return them to wholesalers or destroy them by the March 25 deadline.

Why It Matters to Kratom Merchants and Consumers

This ban represents a critical development for both kratom merchants and consumers. For businesses operating in or shipping to Connecticut, the implications are immediate and severe. All sales and distribution channels to the state must cease, and any existing inventory within Connecticut must be handled in compliance with the new regulations—either returned or destroyed. Failure to comply could result in serious penalties, including felony charges.

Consumers in Connecticut will no longer have legal access to kratom. The state’s move classifies kratom alongside substances like heroin and MDMA, reflecting a stance that it has no accepted medical use and poses significant public health risks due to its addictive potential and lack of regulation.

Compliance Implications for the Kratom Industry

Connecticut's decision makes it the seventh state to designate kratom as a Schedule 1 controlled substance, signaling a growing trend in state-level regulation. This fragmented legal landscape necessitates heightened vigilance for all kratom merchants. Businesses must maintain an up-to-date understanding of kratom's legal status in every jurisdiction they serve, as legality can vary drastically from state to state, and even county to county.

What High-Risk Merchants Need to Know About COAs, Lab Testing, and Regulatory Compliance

For high-risk merchants navigating the complex and evolving kratom market, robust compliance protocols are paramount. While Connecticut's ban eliminates the possibility of legal sales within its borders, the principles of stringent compliance remain critical for operations in legal jurisdictions.

1. Stay Informed: Continuously monitor legislative and regulatory changes at federal, state, and local levels. Membership in industry associations and subscribing to legal updates are crucial.
2. Certificate of Analysis (COA) and Lab Testing: In states where kratom remains legal, comprehensive third-party lab testing and readily available Certificates of Analysis (COAs) are essential. These documents verify product purity, potency, and absence of contaminants, building consumer trust and demonstrating a commitment to safety and quality. While not a shield against outright bans, they are vital for responsible commerce where permitted.
3. Age Verification: Implement robust age verification systems to prevent sales to minors, even in unregulated markets, as a proactive measure against potential future restrictions.
4. Marketing and Claims: Avoid making any unapproved health claims about kratom products. The FDA has not approved kratom for any medical use, and doing so can attract unwanted regulatory scrutiny.
5. Payment Processing: High-risk payment processors specializing in the kratom industry are crucial. They understand the regulatory challenges and can offer solutions that align with compliance requirements in various legal frameworks.

Connecticut's ban underscores the unpredictable nature of the kratom industry's regulatory environment. Merchants must prioritize proactive compliance and adapt quickly to avoid severe legal and financial repercussions.